Abeona Therapeutics (ABEO) Receivables (2010 - 2026)

Abeona Therapeutics' Receivables history runs 17 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• In Q1 2026, Receivables rose 308.16% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (up 308.16% YoY), while the FY2025 annual figure was $5.1 million, up 206.48% from the prior year.
• Receivables for Q1 2026 stood at $6.6 million, up from -$1.0 million in the prior quarter.
• The five-year high for Receivables was $6.6 million in Q1 2026, with the low at -$1.0 million in Q4 2025.
• The 5-year median for Receivables is $1.6 million (2024), against an average of $1.8 million.
• The sharpest annual moves came in 2023 and 2025: Receivables surged 1017.02% in 2023, then plunged 2787.17% in 2025.
• Abeona Therapeutics' Receivables stood at $188000.0 in 2022, then soared by 1017.02% to $2.1 million in 2023, then sank by 98.14% to $39000.0 in 2024, then slumped by 2787.17% to -$1.0 million in 2025, then jumped by 729.77% to $6.6 million in 2026.
• Business Quant data shows ABEO's Receivables at $6.6 million in Q1 2026, -$1.0 million in Q4 2025, and $1.6 million in Q3 2025.